unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after an immunotherapy setback five years ago. The dual immunotherapy combination of Opdivo and Yervoy showed it can ...
Application based on CheckMate -816, the first Phase 3 trial with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in this setting If ...
The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...
Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...
Zacks Investment Research on MSN
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In ...
A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to keeping ...
There is arguably no indication that offers a faster long-term growth rate for drug developers than oncology -- and rightly so with very few cancers being well understood by researchers, and most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback